Jasper Therapeutics to Host Webinar to Present Preliminary Data from the BEACON Study of Briquilimab in Chronic Spontaneous Urticaria on January 8, 2025

Core Viewpoint - Jasper Therapeutics, Inc. is hosting a virtual webinar on January 8, 2025, to present preliminary data from the BEACON study of briquilimab, a novel antibody therapy targeting c-Kit for mast cell driven diseases [1][2] Company Overview - Jasper Therapeutics is a clinical-stage biotechnology company focused on developing briquilimab as a treatment for chronic mast cell diseases, including chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU), and asthma [2] - Briquilimab is an aglycosylated monoclonal antibody that inhibits the binding of stem cell factor to the c-Kit receptor, leading to mast cell depletion and reduction of inflammatory responses [2] - The company has reported positive clinical outcomes for briquilimab in CIndU and is currently conducting clinical studies for its efficacy in CSU, CIndU, and asthma [2] Upcoming Event - The webinar will feature management presentations and remarks from Dr. Thomas B. Casale, a leading investigator in the BEACON study [1]